The purpose of this study is to determine the safety profile and tolerability of S 55746 in patients with CLL, B-Cell NHL and MM, in terms of Dose-Limiting Toxicities (DLTs), Maximum Tolerated Dose (MTD) and determine the Recommended Phase 2 Dose (RP2D) through safety profile (DLT, MTD), PK profile, PD profile and preliminary efficacy.

Inclusion Criteria:

• Women or men aged >/=18 years
• Patients with a measurable histologically confirmed Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), Diffuse Large B-Cell Lymphoma (DLBCL), Small Lymphocytic Lymphoma (SLL) and Marginal Zone Lymphoma (MZL) (Arm A), or patients with an evaluable immunophenotypically confirmed CLL (Arm B), or patients with a measurable Multiple Myeloma t(11;14) (arm A expansion part) according to International Myeloma Working Group (IMWG) criteria
• Relapsed after or refractory disease to standard treatments, and require treatment in the opinion of the investigator
• Estimated life expectancy > 12 weeks
• World Health Organization (WHO) performance status 0-2
• Adequate bone marrow, renal and hepatic functions
• No evidence or treatment for another malignancy within 2 years prior to study entry. Curatively treated non-melanoma skin cancer, in situ carcinoma, or cervical intraepithelial neoplasia is allowed

Additional inclusion criteria for food interaction cohort:

• B-cell NHL patients at low risk of tumour lysis syndrome (TLS)
• Recent/concomitant treatment altering gastric pH

Exclusion Criteria:

• Previous treatment with a BH3 mimetic
• Previous therapy for the studied disease within 3 weeks before first intake
• Radioimmunotherapy, radiotherapy within 8 weeks before first intake
• Major surgery within 3 weeks before first day of study drug dosing
• Corticosteroids >= 20 mg prednisone equivalent per day within 7 days before first intake
• Anticoagulant oral drugs, aspirin > 325 mg/day within 7 days prior to first S 55746 intake
• Positive direct antiglobulin test (Coombs test) and haptoglobin below normal value
• Prior allogenic stem cell transplant
• Autologous stem cell transplant within 3 months before first intake
• NHL patients diagnosed with Post-Transplant Lymphoproliferative Disease, Burkitt's lymphoma, Burkitt-like lymphoma, or lymphoblastic lymphoma/leukaemia
• Human immunodeficiency virus (HIV)
• Known acute or chronic hepatitis B or hepatitis C
• Impaired cardiac function
• Medications known to prolong corrected QT (QTc) interval
• History or/ clinically suspicious for cancer- related Central Nervous System disease
• Solitary extramedullary plasmacytoma
• Laboratory Signs of TLS
• Strong or moderate CYP3A4 inhibitors/inducers (treatment, food or drink products)
• Treatment highly metabolized by the CYP3A4 or CYP2D6 and/or substrates with a narrow therapeutic index, multienzyme and/or OATP and/or P-gp substrates or herbal products.
• Known hypersensitivity to rasburicase
• Glucose-6-phosphate dehydrogenase (G6PD) deficiency and other cellular metabolic disorders known to cause haemolytic anaemia
• Patients receiving proton pump inhibitor

Researchers can ask for a study protocol, patient-level and/or study-level clinical trial data including clinical study reports (CSRs).

They can ask all interventional clinical studies:

• submitted for new medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).
• Where Servier or an affiliate are the Marketing Authorization Holders (MAH). The date of the first Marketing Authorization of the new medicine (or the new indication) in one of the EEA Member States will be considered within this scope.

After Marketing Authorisation in EEA or US if the study is used for the approval.

Researchers should register on Servier Data Portal and fill in the research proposal form. This form in four parts should be fully documented. The Research Proposal Form will not be reviewed until all mandatory fields are completed.